# Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

> **NCT04679064** · PHASE3 · UNKNOWN · sponsor: **Fondazione Policlinico Universitario Agostino Gemelli IRCCS** · enrollment: 427 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Niraparib
- **DRUG:** Dostarlimab
- **DRUG:** Pegylated liposomal doxorubicin
- **DRUG:** Paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Topotecan
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT04679064
- **Lead sponsor:** Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-01
- **Primary completion:** 2025-01-01
- **Final completion:** 2025-01-01
- **Target enrollment:** 427 (ESTIMATED)
- **Last updated:** 2021-08-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04679064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04679064, "Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04679064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*